{"gene":"MARK1","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2004,"finding":"LKB1, in complex with STRAD and MO25, phosphorylates the T-loop threonine of MARK1 (and other AMPK-related kinases), increasing kinase activity >50-fold. Mutation of the T-loop Thr to Ala prevents activation; mutation to Glu produces constitutively active forms. Endogenous MARK1 activity is markedly reduced in LKB1-deficient cells.","method":"In vitro kinase assays, site-directed mutagenesis of T-loop residues, activity measurements in LKB1-deficient cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, confirmed by loss-of-function in endogenous cellular context, replicated across multiple AMPK-subfamily members","pmids":["14976552"],"is_preprint":false},{"year":2003,"finding":"MARKK (a Ste20-family kinase, also called TAO-1) is an upstream activating kinase for MARK. MARKK phosphorylates MARK within its activation loop at T208 (in MARK2 numbering). A fraction of brain MARK is doubly phosphorylated at T208/S212; the second phosphorylation at S212 is inhibitory. MARKK activation of MARK enhances microtubule dynamics through phosphorylation and detachment of tau/MAPs from microtubules.","method":"Co-immunoprecipitation, in vitro kinase assay, phosphorylation site mapping, cell transfection with overexpression and dominant-negative constructs","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase reconstitution with phosphorylation site identification, cell-based validation, single lab but multiple orthogonal methods","pmids":["14517247"],"is_preprint":false},{"year":2007,"finding":"H. pylori CagA specifically interacts with PAR1/MARK kinase. CagA association inhibits PAR1 kinase activity and prevents aPKC-mediated phosphorylation of PAR1 that normally dissociates PAR1 from the membrane, causing junctional and polarity defects. PAR1 also promotes CagA multimerization, stabilizing the CagA–SHP2 interaction. Induction of the hummingbird phenotype by CagA-activated SHP2 requires simultaneous inhibition of PAR1 kinase activity by CagA.","method":"Co-immunoprecipitation, kinase activity assays, dominant-negative and overexpression constructs, cell polarity and junction assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, kinase inhibition assays, multiple functional readouts, published in high-impact journal with multiple orthogonal experiments","pmids":["17507984"],"is_preprint":false},{"year":2002,"finding":"MARK2 (a MARK family member) phosphorylates tau at KXGS motifs in the repeat domain, causing detachment of tau from microtubules and their destabilization. Inactivation of MARK2 by dominant-negative mutant or inhibitors blocks neurite formation in N2a neuroblastoma cells. Rendering the KXGS motifs non-phosphorylatable by point mutations also blocks neurite formation, indicating that MARK-mediated tau phosphorylation is required for microtubule plasticity needed for neuronal polarity and neurite outgrowth.","method":"Dominant-negative transfection, pharmacological inhibition (hymenialdisine), point mutagenesis of tau KXGS motifs, neurite outgrowth assays","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal loss-of-function approaches (dominant-negative, inhibitor, substrate mutagenesis) with defined cellular phenotype","pmids":["12429843"],"is_preprint":false},{"year":2004,"finding":"MARK/Par-1 phosphorylates MAPs (tau, MAP2, MAP4) at KXGS motifs, detaching them from microtubule tracks and thereby facilitating motor-driven vesicle transport. Expression of MARK rescues the transport inhibition of mitochondria, APP vesicles, and other cargoes caused by tau overload in primary retinal ganglion cells, without changing the intrinsic velocity of active motor movement.","method":"Live-cell imaging of vesicle/organelle transport, transfection of MARK and tau constructs in primary neurons and cell lines, quantification of transport parameters","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct imaging of transport rescue in primary neurons, multiple cargo types tested, clear functional mechanism","pmids":["15466480"],"is_preprint":false},{"year":2011,"finding":"Death-associated protein kinase (DAPK) activates MARK1/2 through a direct interaction: the DAPK death domain (not its catalytic domain) binds to the MARK1/2 spacer region, disrupting an intramolecular autoinhibitory interaction within MARK1/2. This DAPK-mediated MARK activation leads to tau/MAP phosphorylation, microtubule destabilization, and modulation of neuronal polarity. In a Drosophila tauopathy model, DAPK acts partly through the MARK ortholog PAR-1 to induce neurodegeneration in a PAR-1 phosphorylation-dependent manner.","method":"Co-immunoprecipitation (DAPK death domain – MARK1/2 spacer), kinase activity assays, DAPK−/− mouse brain phospho-tau analysis, Drosophila genetic epistasis, neurite outgrowth assays","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays, kinase activity, in vivo mouse and Drosophila epistasis, multiple orthogonal methods across labs","pmids":["21311567"],"is_preprint":false},{"year":2016,"finding":"The KA1 domain at the C-terminus of human MARK1 directly interacts with and inhibits the MARK1 kinase domain (autoinhibition). Residues in the KA1 domain required for autoinhibition are the same residues that mediate anionic phospholipid binding. A 'mini' MARK1 becomes activated upon association with anionic phospholipid-containing vesicles, but only when a second membrane-targeting signal is also present, indicating that dual membrane signals are required for relieving autoinhibition.","method":"In vitro kinase assays with isolated domains, site-directed mutagenesis of KA1 domain residues, lipid vesicle binding/activation assays, domain-deletion analysis","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of autoinhibition and phospholipid-dependent activation with mutagenesis, single lab but multiple orthogonal biochemical methods","pmids":["27879374"],"is_preprint":false},{"year":2008,"finding":"MARK family kinases contain multiple regulatory domains (kinase domain, UBA domain, spacer, KA1 domain) that mediate regulation through phosphorylation (activation loop phosphorylation by upstream kinases), protein–protein interactions (14-3-3 proteins, PAK5), and subcellular targeting. PAK5 inactivates MARK not by phosphorylation but by direct binding to the catalytic domain, thereby preventing tau phosphorylation and stabilizing microtubules. MARKK activates MARK by phosphorylating the activation loop threonine. MARK and its regulators mediate crosstalk between actin and microtubule cytoskeletons.","method":"Structural analysis (X-ray crystallography referenced for human MARKs), co-immunoprecipitation, kinase assays, domain analysis","journal":"BMC neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structural and biochemical data combined, but this is a review/summary paper consolidating prior findings; PAK5 binding mechanism is a novel mechanistic point","pmids":["19090997"],"is_preprint":false},{"year":2008,"finding":"MARK1 is identified as a susceptibility gene for autism spectrum disorders. Both overexpression and siRNA-mediated silencing of MARK1 result in significantly shorter dendrite length in mouse neocortical neurons, and MARK1 overexpression modifies dendritic transport speed, demonstrating MARK1's role in axon-dendrite specification and dendritic morphology.","method":"MARK1 overexpression and siRNA knockdown in mouse neocortical neurons, morphometric analysis of dendrite length, dendritic transport quantification","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct gain- and loss-of-function in primary neurons with quantified morphological and transport phenotypes, single lab","pmids":["18492799"],"is_preprint":false},{"year":2018,"finding":"MARK1 is a direct functional target of miR-125a-5p. Luciferase reporter assays confirmed that miR-125a-5p directly binds a predicted target site in the MARK1 3'-UTR. siRNA-mediated knockdown of MARK1 in HeLa and C-33A cervical tumor cells stimulates cell migration, phenocopying the effect of miR-125a-5p overexpression.","method":"Luciferase reporter assay (3'-UTR), siRNA knockdown of MARK1, transwell migration assays, miRNA mimic transfection","journal":"MicroRNA","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'-UTR validation and loss-of-function phenotype, but single lab, functional link between MARK1 and migration established without pathway mechanism","pmids":["29076440"],"is_preprint":false},{"year":2006,"finding":"MARK/Par-1 regulation involves multiple modes: activation loop phosphorylation by MARKK (activating), phosphorylation by aPKC (dissociating from membrane), interaction with 14-3-3 proteins (subcellular targeting/scaffolding), and inhibitory binding by PAK5 to the catalytic domain. PAK5 prevents MARK-induced tau phosphorylation, stabilizes microtubules, and contributes to actin dynamics via cofilin activation, establishing MARK and its regulators as mediators of cytoskeletal crosstalk.","method":"Co-immunoprecipitation, kinase activity assays, transfection/overexpression in cells, phosphorylation site analysis","journal":"Neuro-degenerative diseases","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — consolidates multiple binding and activity results, but largely a review integrating prior single-method findings from multiple studies","pmids":["17047359"],"is_preprint":false},{"year":2016,"finding":"PAR-1/MARK kinases localize and function in opposition to anterior PAR proteins to control asymmetric factor distribution in polarized cells. In mammalian neurons, MARK controls microtubule dynamics; in C. elegans zygote and Drosophila oocyte, PAR-1 (MARK ortholog) establishes anterior/posterior polarity through antagonistic interactions with anterior PAR proteins (including aPKC-mediated phosphorylation of PAR-1 that displaces it from the membrane).","method":"Review consolidating genetic epistasis, localization studies (live imaging, immunofluorescence), and kinase assays across multiple organisms","journal":"Current topics in developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — consolidates well-replicated genetic epistasis and localization data, but is itself a review article","pmids":["28236972"],"is_preprint":false}],"current_model":"MARK1 (PAR-1C) is a serine/threonine kinase that phosphorylates microtubule-associated proteins (tau, MAP2, MAP4) at KXGS motifs in their repeat domains, detaching them from microtubules to regulate microtubule dynamics, axonal transport, and neuronal polarity; its activity is controlled by a hierarchical regulatory network in which LKB1 (with STRAD/MO25) and MARKK/TAO-1 activate it via T-loop phosphorylation, while PAK5 and H. pylori CagA inhibit it through direct binding to the catalytic or regulatory domains, and its C-terminal KA1 domain mediates autoinhibition that is relieved by anionic phospholipids at the membrane."},"narrative":{"mechanistic_narrative":"MARK1 (PAR-1C) is a serine/threonine kinase that controls microtubule dynamics, axonal transport, and neuronal polarity by phosphorylating microtubule-associated proteins (tau, MAP2, MAP4) at KXGS motifs within their repeat domains, detaching them from microtubules [PMID:12429843, PMID:15466480]. This detachment converts microtubule tracks from a tau-blocked to a transport-competent state: MARK expression rescues motor-driven transport of mitochondria and APP vesicles that is otherwise inhibited by tau overload, without altering intrinsic motor velocity [PMID:15466480], and MARK-mediated tau phosphorylation is required for the microtubule plasticity that underlies neurite outgrowth and axon-dendrite specification [PMID:12429843, PMID:18492799]. MARK1 activity is set by a layered regulatory network. Activation requires phosphorylation of the activation-loop threonine, performed by LKB1 in complex with STRAD and MO25 (raising activity >50-fold) and by the Ste20-family kinase MARKK/TAO-1; a second, inhibitory phosphorylation adjacent to the activating site tunes activity [PMID:14976552, PMID:14517247, PMID:19090997]. The C-terminal KA1 domain enforces autoinhibition by binding the kinase domain, using the same residues that bind anionic phospholipids, so that engagement of membrane lipids relieves autoinhibition only when a second membrane-targeting signal is present [PMID:27879374]. Death-associated protein kinase (DAPK) activates MARK1/2 non-catalytically, its death domain binding the MARK spacer to disrupt the intramolecular autoinhibitory interaction [PMID:21311567], whereas PAK5 inactivates MARK by binding the catalytic domain to block tau phosphorylation and stabilize microtubules [PMID:19090997, PMID:17047359]. In epithelia, H. pylori CagA binds and inhibits MARK/PAR1 and shields it from aPKC-mediated phosphorylation that normally displaces it from the membrane, producing junctional and polarity defects [PMID:17507984]. MARK1 has been identified as an autism spectrum disorder susceptibility gene, with both gain and loss of function shortening dendrites in cortical neurons [PMID:18492799].","teleology":[{"year":2002,"claim":"Established the core substrate logic of MARK family kinases: how does phosphorylation of MAPs translate into control of neuronal morphology?","evidence":"Dominant-negative, pharmacological inhibition, and tau KXGS-motif mutagenesis with neurite outgrowth assays in N2a cells","pmids":["12429843"],"confidence":"High","gaps":["Demonstrated for MARK2; isoform-specific contribution of MARK1 to KXGS phosphorylation not resolved here","Endogenous physiological tau pools versus overexpressed substrate not distinguished"]},{"year":2003,"claim":"Identified an upstream activating kinase and the activation-loop site, answering how MARK is switched on and revealing a dual-phosphorylation tuning mechanism.","evidence":"Co-IP, in vitro kinase assays, phosphorylation site mapping, dominant-negative constructs","pmids":["14517247"],"confidence":"High","gaps":["Physiological stimulus driving MARKK/TAO-1 activity unknown","Identity of the kinase setting the inhibitory S212 phosphorylation not established"]},{"year":2004,"claim":"Defined a second activation-loop kinase, placing MARK within the LKB1/AMPK-related kinase hierarchy and establishing T-loop phosphorylation as the master activity switch.","evidence":"In vitro kinase assays, T-loop mutagenesis, activity measurement in LKB1-deficient cells","pmids":["14976552"],"confidence":"High","gaps":["Whether LKB1 and MARKK act redundantly or in distinct contexts on MARK1 unresolved","Spatial/temporal control of LKB1 toward MARK1 not addressed"]},{"year":2004,"claim":"Connected MARK substrate phosphorylation to a concrete cellular output: relief of tau-mediated blockade of axonal transport.","evidence":"Live-cell imaging of mitochondria/APP vesicle transport in primary retinal ganglion neurons with MARK and tau co-expression","pmids":["15466480"],"confidence":"High","gaps":["Endogenous MARK1 contribution under physiological tau levels not isolated","Selectivity among cargo adaptors not dissected"]},{"year":2007,"claim":"Revealed bacterial hijacking of MARK/PAR1 as a polarity effector, defining inhibitory binding and protection from aPKC as a disease-relevant regulatory axis.","evidence":"Reciprocal co-IP, kinase inhibition assays, polarity and junction readouts in epithelial cells","pmids":["17507984"],"confidence":"High","gaps":["MARK1-specific versus pan-PAR1 contribution to the CagA phenotype not separated","Structural basis of CagA-MARK binding not defined here"]},{"year":2008,"claim":"Linked MARK1 to autism susceptibility and to dendritic morphology, establishing a dosage-sensitive neuronal role.","evidence":"Overexpression and siRNA in mouse neocortical neurons with dendrite morphometry and transport quantification","pmids":["18492799"],"confidence":"Medium","gaps":["Mechanistic link between genetic association and dendrite phenotype not fully resolved","Single lab; causal variant function not reconstituted"]},{"year":2008,"claim":"Consolidated the multidomain regulatory architecture and identified PAK5 inhibition by direct catalytic-domain binding rather than phosphorylation.","evidence":"Structural analysis, co-IP, kinase and domain assays (review/summary)","pmids":["19090997"],"confidence":"Medium","gaps":["Review consolidation; some mechanisms not original to this work","14-3-3 targeting specificity for MARK1 not quantitatively defined"]},{"year":2011,"claim":"Defined DAPK as a non-catalytic activator that disrupts MARK autoinhibition, linking MARK activation to tauopathy-associated neurodegeneration.","evidence":"Death-domain/spacer co-IP, kinase assays, DAPK-/- mouse phospho-tau analysis, Drosophila PAR-1 epistasis","pmids":["21311567"],"confidence":"High","gaps":["Structural detail of the death-domain/spacer interaction not resolved","Relative contribution of DAPK versus T-loop kinases in vivo unquantified"]},{"year":2016,"claim":"Established the KA1 domain as the autoinhibitory and membrane-sensing module, defining how anionic phospholipids relieve autoinhibition under a dual-signal requirement.","evidence":"In vitro kinase assays with isolated domains, KA1 mutagenesis, lipid vesicle activation assays","pmids":["27879374"],"confidence":"High","gaps":["Identity of the required second membrane-targeting signal in cells unknown","Integration of KA1-lipid sensing with T-loop phosphorylation not reconstituted"]},{"year":2018,"claim":"Identified post-transcriptional control of MARK1 by miR-125a-5p and a role in tumor cell migration, extending MARK1 function beyond neurons.","evidence":"3'-UTR luciferase reporter, MARK1 siRNA, transwell migration assays in cervical tumor cells","pmids":["29076440"],"confidence":"Medium","gaps":["Downstream pathway linking MARK1 loss to migration not defined","Single lab; no in vivo validation"]},{"year":2016,"claim":"Framed MARK/PAR-1 within conserved cell-polarity logic, antagonizing anterior PAR proteins across organisms.","evidence":"Review consolidating genetic epistasis, localization, and kinase data across C. elegans, Drosophila, and mammals","pmids":["28236972"],"confidence":"Medium","gaps":["Review; mammalian MARK1-specific polarity mechanisms generalized from orthologs","Direct substrates mediating polarity antagonism not enumerated here"]},{"year":null,"claim":"How the multiple inputs (LKB1/MARKK T-loop phosphorylation, DAPK autoinhibition release, KA1-lipid sensing, PAK5/CagA inhibition) are integrated spatially and temporally to set MARK1 activity at specific subcellular sites remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of competing activating and inhibitory inputs in a single cellular context","Endogenous MARK1-specific substrate repertoire beyond tau/MAP2/MAP4 not mapped","Structural basis for membrane-dependent activation in cells unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,4,0,1]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[3,0,1]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[3,4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,6]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[3,4]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,8,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2]}],"complexes":[],"partners":["LKB1","STRAD","MO25","MARKK/TAO1","DAPK","PAK5","CAGA","14-3-3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9P0L2","full_name":"Serine/threonine-protein kinase MARK1","aliases":["MAP/microtubule affinity-regulating kinase 1","PAR1 homolog c","Par-1c","Par1c"],"length_aa":795,"mass_kda":89.0,"function":"Serine/threonine-protein kinase (PubMed:23666762). Involved in cell polarity and microtubule dynamics regulation. Phosphorylates DCX, MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TAU (PubMed:23666762). Involved in cell polarity by phosphorylating the microtubule-associated proteins MAP2, MAP4 and MAPT/TAU at KXGS motifs, causing detachment from microtubules, and their disassembly. Involved in the regulation of neuronal migration through its dual activities in regulating cellular polarity and microtubule dynamics, possibly by phosphorylating and regulating DCX. Also acts as a positive regulator of the Wnt signaling pathway, probably by mediating phosphorylation of dishevelled proteins (DVL1, DVL2 and/or DVL3)","subcellular_location":"Cell membrane; Cytoplasm, cytoskeleton; Cytoplasm; Cell projection, dendrite","url":"https://www.uniprot.org/uniprotkb/Q9P0L2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MARK1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"UTRN","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/MARK1","total_profiled":1310},"omim":[{"mim_id":"610836","title":"AUTISM, SUSCEPTIBILITY TO, 11; AUTS11","url":"https://www.omim.org/entry/610836"},{"mim_id":"610266","title":"TAO KINASE 1; TAOK1","url":"https://www.omim.org/entry/610266"},{"mim_id":"606511","title":"MAP/MICROTUBULE AFFINITY-REGULATING KINASE 1; MARK1","url":"https://www.omim.org/entry/606511"},{"mim_id":"157140","title":"MICROTUBULE-ASSOCIATED PROTEIN TAU; MAPT","url":"https://www.omim.org/entry/157140"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MARK1"},"hgnc":{"alias_symbol":["MARK","PAR-1C"],"prev_symbol":[]},"alphafold":{"accession":"Q9P0L2","domains":[{"cath_id":"3.30.200.20","chopping":"57-138","consensus_level":"medium","plddt":93.1254,"start":57,"end":138},{"cath_id":"1.10.510.10","chopping":"143-312","consensus_level":"high","plddt":92.1915,"start":143,"end":312},{"cath_id":"1.10.8.10","chopping":"334-370","consensus_level":"medium","plddt":95.5451,"start":334,"end":370},{"cath_id":"3.30.310.80","chopping":"710-793","consensus_level":"high","plddt":91.8485,"start":710,"end":793}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9P0L2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9P0L2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9P0L2-F1-predicted_aligned_error_v6.png","plddt_mean":67.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MARK1","jax_strain_url":"https://www.jax.org/strain/search?query=MARK1"},"sequence":{"accession":"Q9P0L2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9P0L2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9P0L2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9P0L2"}},"corpus_meta":[{"pmid":"21248841","id":"PMC_21248841","title":"The Polycomb complex PRC2 and its mark in life.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21248841","citation_count":2648,"is_preprint":false},{"pmid":"16403636","id":"PMC_16403636","title":"Genomic DNA methylation: the mark and its mediators.","date":"2006","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16403636","citation_count":1764,"is_preprint":false},{"pmid":"22473383","id":"PMC_22473383","title":"Histone methylation: a dynamic mark in health, disease and inheritance.","date":"2012","source":"Nature reviews. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22473383","citation_count":1734,"is_preprint":false},{"pmid":"21885730","id":"PMC_21885730","title":"ER tubules mark sites of mitochondrial division.","date":"2011","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21885730","citation_count":1688,"is_preprint":false},{"pmid":"14976552","id":"PMC_14976552","title":"LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/14976552","citation_count":1157,"is_preprint":false},{"pmid":"27618450","id":"PMC_27618450","title":"G-quadruplex structures mark human regulatory chromatin.","date":"2016","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27618450","citation_count":736,"is_preprint":false},{"pmid":"21430292","id":"PMC_21430292","title":"First off the mark: early seed germination.","date":"2011","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/21430292","citation_count":436,"is_preprint":false},{"pmid":"26790532","id":"PMC_26790532","title":"Protein prenylation: unique fats make their mark on biology.","date":"2016","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26790532","citation_count":432,"is_preprint":false},{"pmid":"31485078","id":"PMC_31485078","title":"The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31485078","citation_count":414,"is_preprint":false},{"pmid":"17507984","id":"PMC_17507984","title":"Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17507984","citation_count":404,"is_preprint":false},{"pmid":"26121748","id":"PMC_26121748","title":"High IFN-γ and low SLPI mark severe asthma in mice and humans.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26121748","citation_count":332,"is_preprint":false},{"pmid":"28450738","id":"PMC_28450738","title":"DNA methylation: an epigenetic mark of cellular memory.","date":"2017","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28450738","citation_count":314,"is_preprint":false},{"pmid":"16496001","id":"PMC_16496001","title":"Eisosomes mark static sites of endocytosis.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16496001","citation_count":293,"is_preprint":false},{"pmid":"30311405","id":"PMC_30311405","title":"The dynamic RNA modification 5-methylcytosine and its emerging role as an epitranscriptomic mark.","date":"2018","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/30311405","citation_count":276,"is_preprint":false},{"pmid":"17466503","id":"PMC_17466503","title":"Genomic patterns of DNA methylation: targets and function of an epigenetic mark.","date":"2007","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17466503","citation_count":273,"is_preprint":false},{"pmid":"27940208","id":"PMC_27940208","title":"H3K27 methylation: a promiscuous repressive chromatin mark.","date":"2016","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/27940208","citation_count":243,"is_preprint":false},{"pmid":"12429843","id":"PMC_12429843","title":"Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity.","date":"2002","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/12429843","citation_count":215,"is_preprint":false},{"pmid":"27076075","id":"PMC_27076075","title":"Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot.","date":"2016","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27076075","citation_count":207,"is_preprint":false},{"pmid":"15466480","id":"PMC_15466480","title":"MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons.","date":"2004","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15466480","citation_count":190,"is_preprint":false},{"pmid":"30154464","id":"PMC_30154464","title":"Lysine benzoylation is a histone mark regulated by SIRT2.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30154464","citation_count":181,"is_preprint":false},{"pmid":"19559622","id":"PMC_19559622","title":"The tau of MARK: a polarized view of the cytoskeleton.","date":"2009","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19559622","citation_count":178,"is_preprint":false},{"pmid":"34238359","id":"PMC_34238359","title":"The dynamic broad epigenetic (H3K4me3, H3K27ac) domain as a mark of essential genes.","date":"2021","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/34238359","citation_count":176,"is_preprint":false},{"pmid":"26507168","id":"PMC_26507168","title":"DNA N(6)-methyladenine: a new epigenetic mark in eukaryotes?","date":"2015","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26507168","citation_count":167,"is_preprint":false},{"pmid":"12853203","id":"PMC_12853203","title":"Targeting epidermal growth factor receptor--are we missing the mark?","date":"2003","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12853203","citation_count":165,"is_preprint":false},{"pmid":"14517247","id":"PMC_14517247","title":"MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/14517247","citation_count":165,"is_preprint":false},{"pmid":"34627643","id":"PMC_34627643","title":"Histone lactylation: epigenetic mark of glycolytic switch.","date":"2021","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/34627643","citation_count":156,"is_preprint":false},{"pmid":"23927873","id":"PMC_23927873","title":"Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation.","date":"2013","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/23927873","citation_count":136,"is_preprint":false},{"pmid":"15536132","id":"PMC_15536132","title":"Dynamic histone modifications mark sex chromosome inactivation and reactivation during mammalian spermatogenesis.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15536132","citation_count":132,"is_preprint":false},{"pmid":"21168777","id":"PMC_21168777","title":"Ubiquitin makes its mark on immune regulation.","date":"2010","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21168777","citation_count":126,"is_preprint":false},{"pmid":"27477906","id":"PMC_27477906","title":"ZMYND8 Reads the Dual Histone Mark H3K4me1-H3K14ac to Antagonize the Expression of Metastasis-Linked Genes.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27477906","citation_count":124,"is_preprint":false},{"pmid":"24382391","id":"PMC_24382391","title":"Cancer epigenetics drug discovery and development: the challenge of hitting the mark.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24382391","citation_count":115,"is_preprint":false},{"pmid":"19356248","id":"PMC_19356248","title":"Histone acetylations mark origins of polycistronic transcription in Leishmania major.","date":"2009","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/19356248","citation_count":115,"is_preprint":false},{"pmid":"23414304","id":"PMC_23414304","title":"The chromatin response to DNA breaks: leaving a mark on genome integrity.","date":"2013","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23414304","citation_count":107,"is_preprint":false},{"pmid":"12669083","id":"PMC_12669083","title":"Yeasts make their mark.","date":"2003","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12669083","citation_count":99,"is_preprint":false},{"pmid":"29080091","id":"PMC_29080091","title":"Post-translational add-ons mark the path in exosomal protein sorting.","date":"2017","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/29080091","citation_count":94,"is_preprint":false},{"pmid":"27826841","id":"PMC_27826841","title":"N6-Methyladenine: A Conserved and Dynamic DNA Mark.","date":"2016","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/27826841","citation_count":91,"is_preprint":false},{"pmid":"17122774","id":"PMC_17122774","title":"Clustered DNA motifs mark X chromosomes for repression by a dosage compensation complex.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17122774","citation_count":89,"is_preprint":false},{"pmid":"15182702","id":"PMC_15182702","title":"An overview of the KIN1/PAR-1/MARK kinase family.","date":"2004","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15182702","citation_count":86,"is_preprint":false},{"pmid":"33485722","id":"PMC_33485722","title":"CARM1/PRMT4: Making Its Mark beyond Its Function as a Transcriptional Coactivator.","date":"2021","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/33485722","citation_count":84,"is_preprint":false},{"pmid":"17346757","id":"PMC_17346757","title":"A site to remember: H3K36 methylation a mark for histone deacetylation.","date":"2007","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/17346757","citation_count":82,"is_preprint":false},{"pmid":"22547698","id":"PMC_22547698","title":"Delays and diversions mark the development of B cell responses to Borrelia burgdorferi infection.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22547698","citation_count":82,"is_preprint":false},{"pmid":"18692077","id":"PMC_18692077","title":"The MBD protein family-reading an epigenetic mark?","date":"2008","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/18692077","citation_count":81,"is_preprint":false},{"pmid":"19242104","id":"PMC_19242104","title":"Replication timing as an epigenetic mark.","date":"2009","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19242104","citation_count":81,"is_preprint":false},{"pmid":"25579174","id":"PMC_25579174","title":"5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25579174","citation_count":80,"is_preprint":false},{"pmid":"35955429","id":"PMC_35955429","title":"Plant DNA Methylation: An Epigenetic Mark in Development, Environmental Interactions, and Evolution.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35955429","citation_count":78,"is_preprint":false},{"pmid":"24921003","id":"PMC_24921003","title":"Role of PRMTs in cancer: Could minor isoforms be leaving a mark?","date":"2014","source":"World journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24921003","citation_count":76,"is_preprint":false},{"pmid":"21311567","id":"PMC_21311567","title":"DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity.","date":"2011","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/21311567","citation_count":73,"is_preprint":false},{"pmid":"28618265","id":"PMC_28618265","title":"Making the Mark: The Role of Adenosine Modifications in the Life Cycle of RNA Viruses.","date":"2017","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/28618265","citation_count":73,"is_preprint":false},{"pmid":"27036066","id":"PMC_27036066","title":"Enigmatic 5-hydroxymethyluracil: Oxidatively modified base, epigenetic mark or both?","date":"2016","source":"Mutation research. Reviews in mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/27036066","citation_count":67,"is_preprint":false},{"pmid":"19369112","id":"PMC_19369112","title":"Does chromatin remodeling mark systemic acquired resistance?","date":"2009","source":"Trends in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/19369112","citation_count":67,"is_preprint":false},{"pmid":"25305461","id":"PMC_25305461","title":"Role of the N6-methyladenosine RNA mark in gene regulation and its implications on development and disease.","date":"2014","source":"Briefings in functional genomics","url":"https://pubmed.ncbi.nlm.nih.gov/25305461","citation_count":66,"is_preprint":false},{"pmid":"34288807","id":"PMC_34288807","title":"RNA 5-methylcytosine modification and its emerging role as an epitranscriptomic mark.","date":"2021","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/34288807","citation_count":65,"is_preprint":false},{"pmid":"31266517","id":"PMC_31266517","title":"H3K4me2 functions as a repressive epigenetic mark in plants.","date":"2019","source":"Epigenetics & chromatin","url":"https://pubmed.ncbi.nlm.nih.gov/31266517","citation_count":64,"is_preprint":false},{"pmid":"18492799","id":"PMC_18492799","title":"Convergent evidence identifying MAP/microtubule affinity-regulating kinase 1 (MARK1) as a susceptibility gene for autism.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18492799","citation_count":63,"is_preprint":false},{"pmid":"36795828","id":"PMC_36795828","title":"Menin \"reads\" H3K79me2 mark in a nucleosomal context.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/36795828","citation_count":62,"is_preprint":false},{"pmid":"24631869","id":"PMC_24631869","title":"Hitting the 'mark': interpreting lysine methylation in the context of active transcription.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24631869","citation_count":62,"is_preprint":false},{"pmid":"22842880","id":"PMC_22842880","title":"5-Hydroxymethylcytosine--the elusive epigenetic mark in mammalian DNA.","date":"2012","source":"Chemical Society reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22842880","citation_count":61,"is_preprint":false},{"pmid":"17721078","id":"PMC_17721078","title":"The Par-1/MARK family of protein kinases: from polarity to metabolism.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17721078","citation_count":58,"is_preprint":false},{"pmid":"27580037","id":"PMC_27580037","title":"PionX sites mark the X chromosome for dosage compensation.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/27580037","citation_count":58,"is_preprint":false},{"pmid":"21278294","id":"PMC_21278294","title":"Accessibility and evolutionary conservation mark bacterial small-rna target-binding regions.","date":"2011","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/21278294","citation_count":58,"is_preprint":false},{"pmid":"27634149","id":"PMC_27634149","title":"DNA methylation: a permissive mark in memory formation and maintenance.","date":"2016","source":"Learning & memory (Cold Spring Harbor, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/27634149","citation_count":56,"is_preprint":false},{"pmid":"23628286","id":"PMC_23628286","title":"Cell-free expression--making a mark.","date":"2013","source":"Current opinion in structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/23628286","citation_count":55,"is_preprint":false},{"pmid":"19090997","id":"PMC_19090997","title":"Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein.","date":"2008","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19090997","citation_count":54,"is_preprint":false},{"pmid":"20735237","id":"PMC_20735237","title":"Decoding the histone H4 lysine 20 methylation mark.","date":"2010","source":"Critical reviews in biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20735237","citation_count":50,"is_preprint":false},{"pmid":"33244833","id":"PMC_33244833","title":"DNA adenine methylation in eukaryotes: Enzymatic mark or a form of DNA damage?","date":"2020","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33244833","citation_count":48,"is_preprint":false},{"pmid":"21416623","id":"PMC_21416623","title":"Role of LKB1-SAD/MARK pathway in neuronal polarization.","date":"2011","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21416623","citation_count":48,"is_preprint":false},{"pmid":"34316718","id":"PMC_34316718","title":"G-quadruplexes mark alternative lengthening of telomeres.","date":"2021","source":"NAR cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34316718","citation_count":46,"is_preprint":false},{"pmid":"23625014","id":"PMC_23625014","title":"On your histone mark, SET, methylate!","date":"2013","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/23625014","citation_count":46,"is_preprint":false},{"pmid":"17047359","id":"PMC_17047359","title":"Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation.","date":"2006","source":"Neuro-degenerative diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17047359","citation_count":46,"is_preprint":false},{"pmid":"31858687","id":"PMC_31858687","title":"Hdac3, Setdb1, and Kap1 mark H3K9me3/H3K14ac bivalent regions in young and aged liver.","date":"2019","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/31858687","citation_count":43,"is_preprint":false},{"pmid":"24517927","id":"PMC_24517927","title":"Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.","date":"2014","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/24517927","citation_count":42,"is_preprint":false},{"pmid":"28236972","id":"PMC_28236972","title":"Regulation of Cell Polarity by PAR-1/MARK Kinase.","date":"2016","source":"Current topics in developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28236972","citation_count":41,"is_preprint":false},{"pmid":"35228526","id":"PMC_35228526","title":"Bacterial N4-methylcytosine as an epigenetic mark in eukaryotic DNA.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35228526","citation_count":41,"is_preprint":false},{"pmid":"19052657","id":"PMC_19052657","title":"CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus.","date":"2008","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/19052657","citation_count":41,"is_preprint":false},{"pmid":"32023084","id":"PMC_32023084","title":"PDGFRα and αSMA mark two distinct mesenchymal cell populations involved in parenchymal and vascular remodeling in pulmonary fibrosis.","date":"2020","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32023084","citation_count":41,"is_preprint":false},{"pmid":"30620902","id":"PMC_30620902","title":"Neurog3-Independent Methylation Is the Earliest Detectable Mark Distinguishing Pancreatic Progenitor Identity.","date":"2019","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/30620902","citation_count":40,"is_preprint":false},{"pmid":"25820690","id":"PMC_25820690","title":"H3K27me3 is an Epigenetic Mark of Relevance in Endometriosis.","date":"2015","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/25820690","citation_count":40,"is_preprint":false},{"pmid":"31522976","id":"PMC_31522976","title":"Lgr5 and Col22a1 Mark Progenitor Cells in the Lineage toward Juvenile Articular Chondrocytes.","date":"2019","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31522976","citation_count":39,"is_preprint":false},{"pmid":"36868209","id":"PMC_36868209","title":"Linking chromatin acylation mark-defined proteome and genome in living cells.","date":"2023","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/36868209","citation_count":38,"is_preprint":false},{"pmid":"29858375","id":"PMC_29858375","title":"Understanding the Histone DNA Repair Code: H4K20me2 Makes Its Mark.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/29858375","citation_count":37,"is_preprint":false},{"pmid":"24831281","id":"PMC_24831281","title":"Pharmacodynamic biomarkers: falling short of the mark?","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24831281","citation_count":37,"is_preprint":false},{"pmid":"27535791","id":"PMC_27535791","title":"Cooperation between the H3K27me3 Chromatin Mark and Non-CG Methylation in Epigenetic Regulation.","date":"2016","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27535791","citation_count":37,"is_preprint":false},{"pmid":"23075511","id":"PMC_23075511","title":"Cytosine methylation and hydroxymethylation mark DNA for elimination in Oxytricha trifallax.","date":"2012","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/23075511","citation_count":36,"is_preprint":false},{"pmid":"28289707","id":"PMC_28289707","title":"Eomesodermin and T-bet mark developmentally distinct human natural killer cells.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/28289707","citation_count":36,"is_preprint":false},{"pmid":"34545082","id":"PMC_34545082","title":"Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34545082","citation_count":36,"is_preprint":false},{"pmid":"21671358","id":"PMC_21671358","title":"Epigenetics, development, and cancer: zebrafish make their mark.","date":"2011","source":"Birth defects research. Part C, Embryo today : reviews","url":"https://pubmed.ncbi.nlm.nih.gov/21671358","citation_count":35,"is_preprint":false},{"pmid":"34731255","id":"PMC_34731255","title":"Nucleotide excision repair leaves a mark on chromatin: DNA damage detection in nucleosomes.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/34731255","citation_count":34,"is_preprint":false},{"pmid":"35562338","id":"PMC_35562338","title":"Microbial functional changes mark irreversible course of Tibetan grassland degradation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35562338","citation_count":33,"is_preprint":false},{"pmid":"39509324","id":"PMC_39509324","title":"Gpnmb and Spp1 mark a conserved macrophage injury response masking fibrosis-specific programming in the lung.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39509324","citation_count":32,"is_preprint":false},{"pmid":"33284953","id":"PMC_33284953","title":"Detection methods of epitranscriptomic mark N6-methyladenosine.","date":"2020","source":"Essays in biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33284953","citation_count":31,"is_preprint":false},{"pmid":"26293475","id":"PMC_26293475","title":"N6-methyladenine functions as a potential epigenetic mark in eukaryotes.","date":"2015","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26293475","citation_count":31,"is_preprint":false},{"pmid":"25262242","id":"PMC_25262242","title":"Canonical and noncanonical roles of Par-1/MARK kinases in cell migration.","date":"2014","source":"International review of cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25262242","citation_count":29,"is_preprint":false},{"pmid":"33376192","id":"PMC_33376192","title":"A mark of disease: how mRNA modifications shape genetic and acquired pathologies.","date":"2020","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33376192","citation_count":29,"is_preprint":false},{"pmid":"31746185","id":"PMC_31746185","title":"TCF19 Promotes Cell Proliferation through Binding to the Histone H3K4me3 Mark.","date":"2019","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31746185","citation_count":27,"is_preprint":false},{"pmid":"29076440","id":"PMC_29076440","title":"MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells.","date":"2018","source":"MicroRNA (Shariqah, United Arab Emirates)","url":"https://pubmed.ncbi.nlm.nih.gov/29076440","citation_count":26,"is_preprint":false},{"pmid":"18511253","id":"PMC_18511253","title":"MYSTs mark chromatin for chromosomal functions.","date":"2008","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18511253","citation_count":26,"is_preprint":false},{"pmid":"21649736","id":"PMC_21649736","title":"DNA hypermethylation as an epigenetic mark for oral cancer diagnosis.","date":"2011","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21649736","citation_count":26,"is_preprint":false},{"pmid":"31837302","id":"PMC_31837302","title":"Loss of the Epigenetic Mark 5-hmC in Psoriasis: Implications for Epidermal Stem Cell Dysregulation.","date":"2019","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/31837302","citation_count":26,"is_preprint":false},{"pmid":"34654832","id":"PMC_34654832","title":"Photoactivatable ribonucleosides mark base-specific RNA-binding sites.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34654832","citation_count":25,"is_preprint":false},{"pmid":"27879374","id":"PMC_27879374","title":"Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase.","date":"2016","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27879374","citation_count":25,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38902,"output_tokens":3518,"usd":0.084738,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11111,"output_tokens":3759,"usd":0.074765,"stage2_stop_reason":"end_turn"},"total_usd":0.159503,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"LKB1, in complex with STRAD and MO25, phosphorylates the T-loop threonine of MARK1 (and other AMPK-related kinases), increasing kinase activity >50-fold. Mutation of the T-loop Thr to Ala prevents activation; mutation to Glu produces constitutively active forms. Endogenous MARK1 activity is markedly reduced in LKB1-deficient cells.\",\n      \"method\": \"In vitro kinase assays, site-directed mutagenesis of T-loop residues, activity measurements in LKB1-deficient cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, confirmed by loss-of-function in endogenous cellular context, replicated across multiple AMPK-subfamily members\",\n      \"pmids\": [\"14976552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MARKK (a Ste20-family kinase, also called TAO-1) is an upstream activating kinase for MARK. MARKK phosphorylates MARK within its activation loop at T208 (in MARK2 numbering). A fraction of brain MARK is doubly phosphorylated at T208/S212; the second phosphorylation at S212 is inhibitory. MARKK activation of MARK enhances microtubule dynamics through phosphorylation and detachment of tau/MAPs from microtubules.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, phosphorylation site mapping, cell transfection with overexpression and dominant-negative constructs\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase reconstitution with phosphorylation site identification, cell-based validation, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"14517247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"H. pylori CagA specifically interacts with PAR1/MARK kinase. CagA association inhibits PAR1 kinase activity and prevents aPKC-mediated phosphorylation of PAR1 that normally dissociates PAR1 from the membrane, causing junctional and polarity defects. PAR1 also promotes CagA multimerization, stabilizing the CagA–SHP2 interaction. Induction of the hummingbird phenotype by CagA-activated SHP2 requires simultaneous inhibition of PAR1 kinase activity by CagA.\",\n      \"method\": \"Co-immunoprecipitation, kinase activity assays, dominant-negative and overexpression constructs, cell polarity and junction assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, kinase inhibition assays, multiple functional readouts, published in high-impact journal with multiple orthogonal experiments\",\n      \"pmids\": [\"17507984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MARK2 (a MARK family member) phosphorylates tau at KXGS motifs in the repeat domain, causing detachment of tau from microtubules and their destabilization. Inactivation of MARK2 by dominant-negative mutant or inhibitors blocks neurite formation in N2a neuroblastoma cells. Rendering the KXGS motifs non-phosphorylatable by point mutations also blocks neurite formation, indicating that MARK-mediated tau phosphorylation is required for microtubule plasticity needed for neuronal polarity and neurite outgrowth.\",\n      \"method\": \"Dominant-negative transfection, pharmacological inhibition (hymenialdisine), point mutagenesis of tau KXGS motifs, neurite outgrowth assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal loss-of-function approaches (dominant-negative, inhibitor, substrate mutagenesis) with defined cellular phenotype\",\n      \"pmids\": [\"12429843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MARK/Par-1 phosphorylates MAPs (tau, MAP2, MAP4) at KXGS motifs, detaching them from microtubule tracks and thereby facilitating motor-driven vesicle transport. Expression of MARK rescues the transport inhibition of mitochondria, APP vesicles, and other cargoes caused by tau overload in primary retinal ganglion cells, without changing the intrinsic velocity of active motor movement.\",\n      \"method\": \"Live-cell imaging of vesicle/organelle transport, transfection of MARK and tau constructs in primary neurons and cell lines, quantification of transport parameters\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct imaging of transport rescue in primary neurons, multiple cargo types tested, clear functional mechanism\",\n      \"pmids\": [\"15466480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Death-associated protein kinase (DAPK) activates MARK1/2 through a direct interaction: the DAPK death domain (not its catalytic domain) binds to the MARK1/2 spacer region, disrupting an intramolecular autoinhibitory interaction within MARK1/2. This DAPK-mediated MARK activation leads to tau/MAP phosphorylation, microtubule destabilization, and modulation of neuronal polarity. In a Drosophila tauopathy model, DAPK acts partly through the MARK ortholog PAR-1 to induce neurodegeneration in a PAR-1 phosphorylation-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation (DAPK death domain – MARK1/2 spacer), kinase activity assays, DAPK−/− mouse brain phospho-tau analysis, Drosophila genetic epistasis, neurite outgrowth assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays, kinase activity, in vivo mouse and Drosophila epistasis, multiple orthogonal methods across labs\",\n      \"pmids\": [\"21311567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The KA1 domain at the C-terminus of human MARK1 directly interacts with and inhibits the MARK1 kinase domain (autoinhibition). Residues in the KA1 domain required for autoinhibition are the same residues that mediate anionic phospholipid binding. A 'mini' MARK1 becomes activated upon association with anionic phospholipid-containing vesicles, but only when a second membrane-targeting signal is also present, indicating that dual membrane signals are required for relieving autoinhibition.\",\n      \"method\": \"In vitro kinase assays with isolated domains, site-directed mutagenesis of KA1 domain residues, lipid vesicle binding/activation assays, domain-deletion analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of autoinhibition and phospholipid-dependent activation with mutagenesis, single lab but multiple orthogonal biochemical methods\",\n      \"pmids\": [\"27879374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MARK family kinases contain multiple regulatory domains (kinase domain, UBA domain, spacer, KA1 domain) that mediate regulation through phosphorylation (activation loop phosphorylation by upstream kinases), protein–protein interactions (14-3-3 proteins, PAK5), and subcellular targeting. PAK5 inactivates MARK not by phosphorylation but by direct binding to the catalytic domain, thereby preventing tau phosphorylation and stabilizing microtubules. MARKK activates MARK by phosphorylating the activation loop threonine. MARK and its regulators mediate crosstalk between actin and microtubule cytoskeletons.\",\n      \"method\": \"Structural analysis (X-ray crystallography referenced for human MARKs), co-immunoprecipitation, kinase assays, domain analysis\",\n      \"journal\": \"BMC neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structural and biochemical data combined, but this is a review/summary paper consolidating prior findings; PAK5 binding mechanism is a novel mechanistic point\",\n      \"pmids\": [\"19090997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MARK1 is identified as a susceptibility gene for autism spectrum disorders. Both overexpression and siRNA-mediated silencing of MARK1 result in significantly shorter dendrite length in mouse neocortical neurons, and MARK1 overexpression modifies dendritic transport speed, demonstrating MARK1's role in axon-dendrite specification and dendritic morphology.\",\n      \"method\": \"MARK1 overexpression and siRNA knockdown in mouse neocortical neurons, morphometric analysis of dendrite length, dendritic transport quantification\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct gain- and loss-of-function in primary neurons with quantified morphological and transport phenotypes, single lab\",\n      \"pmids\": [\"18492799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MARK1 is a direct functional target of miR-125a-5p. Luciferase reporter assays confirmed that miR-125a-5p directly binds a predicted target site in the MARK1 3'-UTR. siRNA-mediated knockdown of MARK1 in HeLa and C-33A cervical tumor cells stimulates cell migration, phenocopying the effect of miR-125a-5p overexpression.\",\n      \"method\": \"Luciferase reporter assay (3'-UTR), siRNA knockdown of MARK1, transwell migration assays, miRNA mimic transfection\",\n      \"journal\": \"MicroRNA\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'-UTR validation and loss-of-function phenotype, but single lab, functional link between MARK1 and migration established without pathway mechanism\",\n      \"pmids\": [\"29076440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MARK/Par-1 regulation involves multiple modes: activation loop phosphorylation by MARKK (activating), phosphorylation by aPKC (dissociating from membrane), interaction with 14-3-3 proteins (subcellular targeting/scaffolding), and inhibitory binding by PAK5 to the catalytic domain. PAK5 prevents MARK-induced tau phosphorylation, stabilizes microtubules, and contributes to actin dynamics via cofilin activation, establishing MARK and its regulators as mediators of cytoskeletal crosstalk.\",\n      \"method\": \"Co-immunoprecipitation, kinase activity assays, transfection/overexpression in cells, phosphorylation site analysis\",\n      \"journal\": \"Neuro-degenerative diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — consolidates multiple binding and activity results, but largely a review integrating prior single-method findings from multiple studies\",\n      \"pmids\": [\"17047359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PAR-1/MARK kinases localize and function in opposition to anterior PAR proteins to control asymmetric factor distribution in polarized cells. In mammalian neurons, MARK controls microtubule dynamics; in C. elegans zygote and Drosophila oocyte, PAR-1 (MARK ortholog) establishes anterior/posterior polarity through antagonistic interactions with anterior PAR proteins (including aPKC-mediated phosphorylation of PAR-1 that displaces it from the membrane).\",\n      \"method\": \"Review consolidating genetic epistasis, localization studies (live imaging, immunofluorescence), and kinase assays across multiple organisms\",\n      \"journal\": \"Current topics in developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — consolidates well-replicated genetic epistasis and localization data, but is itself a review article\",\n      \"pmids\": [\"28236972\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MARK1 (PAR-1C) is a serine/threonine kinase that phosphorylates microtubule-associated proteins (tau, MAP2, MAP4) at KXGS motifs in their repeat domains, detaching them from microtubules to regulate microtubule dynamics, axonal transport, and neuronal polarity; its activity is controlled by a hierarchical regulatory network in which LKB1 (with STRAD/MO25) and MARKK/TAO-1 activate it via T-loop phosphorylation, while PAK5 and H. pylori CagA inhibit it through direct binding to the catalytic or regulatory domains, and its C-terminal KA1 domain mediates autoinhibition that is relieved by anionic phospholipids at the membrane.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MARK1 (PAR-1C) is a serine/threonine kinase that controls microtubule dynamics, axonal transport, and neuronal polarity by phosphorylating microtubule-associated proteins (tau, MAP2, MAP4) at KXGS motifs within their repeat domains, detaching them from microtubules [#3, #4]. This detachment converts microtubule tracks from a tau-blocked to a transport-competent state: MARK expression rescues motor-driven transport of mitochondria and APP vesicles that is otherwise inhibited by tau overload, without altering intrinsic motor velocity [#4], and MARK-mediated tau phosphorylation is required for the microtubule plasticity that underlies neurite outgrowth and axon-dendrite specification [#3, #8]. MARK1 activity is set by a layered regulatory network. Activation requires phosphorylation of the activation-loop threonine, performed by LKB1 in complex with STRAD and MO25 (raising activity >50-fold) and by the Ste20-family kinase MARKK/TAO-1; a second, inhibitory phosphorylation adjacent to the activating site tunes activity [#0, #1, #7]. The C-terminal KA1 domain enforces autoinhibition by binding the kinase domain, using the same residues that bind anionic phospholipids, so that engagement of membrane lipids relieves autoinhibition only when a second membrane-targeting signal is present [#6]. Death-associated protein kinase (DAPK) activates MARK1/2 non-catalytically, its death domain binding the MARK spacer to disrupt the intramolecular autoinhibitory interaction [#5], whereas PAK5 inactivates MARK by binding the catalytic domain to block tau phosphorylation and stabilize microtubules [#7, #10]. In epithelia, H. pylori CagA binds and inhibits MARK/PAR1 and shields it from aPKC-mediated phosphorylation that normally displaces it from the membrane, producing junctional and polarity defects [#2]. MARK1 has been identified as an autism spectrum disorder susceptibility gene, with both gain and loss of function shortening dendrites in cortical neurons [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established the core substrate logic of MARK family kinases: how does phosphorylation of MAPs translate into control of neuronal morphology?\",\n      \"evidence\": \"Dominant-negative, pharmacological inhibition, and tau KXGS-motif mutagenesis with neurite outgrowth assays in N2a cells\",\n      \"pmids\": [\"12429843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Demonstrated for MARK2; isoform-specific contribution of MARK1 to KXGS phosphorylation not resolved here\", \"Endogenous physiological tau pools versus overexpressed substrate not distinguished\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified an upstream activating kinase and the activation-loop site, answering how MARK is switched on and revealing a dual-phosphorylation tuning mechanism.\",\n      \"evidence\": \"Co-IP, in vitro kinase assays, phosphorylation site mapping, dominant-negative constructs\",\n      \"pmids\": [\"14517247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological stimulus driving MARKK/TAO-1 activity unknown\", \"Identity of the kinase setting the inhibitory S212 phosphorylation not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined a second activation-loop kinase, placing MARK within the LKB1/AMPK-related kinase hierarchy and establishing T-loop phosphorylation as the master activity switch.\",\n      \"evidence\": \"In vitro kinase assays, T-loop mutagenesis, activity measurement in LKB1-deficient cells\",\n      \"pmids\": [\"14976552\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LKB1 and MARKK act redundantly or in distinct contexts on MARK1 unresolved\", \"Spatial/temporal control of LKB1 toward MARK1 not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected MARK substrate phosphorylation to a concrete cellular output: relief of tau-mediated blockade of axonal transport.\",\n      \"evidence\": \"Live-cell imaging of mitochondria/APP vesicle transport in primary retinal ganglion neurons with MARK and tau co-expression\",\n      \"pmids\": [\"15466480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous MARK1 contribution under physiological tau levels not isolated\", \"Selectivity among cargo adaptors not dissected\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed bacterial hijacking of MARK/PAR1 as a polarity effector, defining inhibitory binding and protection from aPKC as a disease-relevant regulatory axis.\",\n      \"evidence\": \"Reciprocal co-IP, kinase inhibition assays, polarity and junction readouts in epithelial cells\",\n      \"pmids\": [\"17507984\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MARK1-specific versus pan-PAR1 contribution to the CagA phenotype not separated\", \"Structural basis of CagA-MARK binding not defined here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linked MARK1 to autism susceptibility and to dendritic morphology, establishing a dosage-sensitive neuronal role.\",\n      \"evidence\": \"Overexpression and siRNA in mouse neocortical neurons with dendrite morphometry and transport quantification\",\n      \"pmids\": [\"18492799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between genetic association and dendrite phenotype not fully resolved\", \"Single lab; causal variant function not reconstituted\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Consolidated the multidomain regulatory architecture and identified PAK5 inhibition by direct catalytic-domain binding rather than phosphorylation.\",\n      \"evidence\": \"Structural analysis, co-IP, kinase and domain assays (review/summary)\",\n      \"pmids\": [\"19090997\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review consolidation; some mechanisms not original to this work\", \"14-3-3 targeting specificity for MARK1 not quantitatively defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined DAPK as a non-catalytic activator that disrupts MARK autoinhibition, linking MARK activation to tauopathy-associated neurodegeneration.\",\n      \"evidence\": \"Death-domain/spacer co-IP, kinase assays, DAPK-/- mouse phospho-tau analysis, Drosophila PAR-1 epistasis\",\n      \"pmids\": [\"21311567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of the death-domain/spacer interaction not resolved\", \"Relative contribution of DAPK versus T-loop kinases in vivo unquantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established the KA1 domain as the autoinhibitory and membrane-sensing module, defining how anionic phospholipids relieve autoinhibition under a dual-signal requirement.\",\n      \"evidence\": \"In vitro kinase assays with isolated domains, KA1 mutagenesis, lipid vesicle activation assays\",\n      \"pmids\": [\"27879374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the required second membrane-targeting signal in cells unknown\", \"Integration of KA1-lipid sensing with T-loop phosphorylation not reconstituted\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified post-transcriptional control of MARK1 by miR-125a-5p and a role in tumor cell migration, extending MARK1 function beyond neurons.\",\n      \"evidence\": \"3'-UTR luciferase reporter, MARK1 siRNA, transwell migration assays in cervical tumor cells\",\n      \"pmids\": [\"29076440\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream pathway linking MARK1 loss to migration not defined\", \"Single lab; no in vivo validation\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Framed MARK/PAR-1 within conserved cell-polarity logic, antagonizing anterior PAR proteins across organisms.\",\n      \"evidence\": \"Review consolidating genetic epistasis, localization, and kinase data across C. elegans, Drosophila, and mammals\",\n      \"pmids\": [\"28236972\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review; mammalian MARK1-specific polarity mechanisms generalized from orthologs\", \"Direct substrates mediating polarity antagonism not enumerated here\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple inputs (LKB1/MARKK T-loop phosphorylation, DAPK autoinhibition release, KA1-lipid sensing, PAK5/CagA inhibition) are integrated spatially and temporally to set MARK1 activity at specific subcellular sites remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of competing activating and inhibitory inputs in a single cellular context\", \"Endogenous MARK1-specific substrate repertoire beyond tau/MAP2/MAP4 not mapped\", \"Structural basis for membrane-dependent activation in cells unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 4, 0, 1]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [3, 0, 1]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 8, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LKB1\", \"STRAD\", \"MO25\", \"MARKK/TAO1\", \"DAPK\", \"PAK5\", \"CagA\", \"14-3-3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}